TargetBeta
TOP2A
DNA topoisomerase II alpha · also TOP2alpha, TOPIIA, TOP2 · Topoisomerases
4 programs in company-led studies act on TOP2A, from 3 companies: 3 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Doxorubicinrule | Hoffmann-La Roche | phase 4 | 619 running | – | ChEMBL |
| Etoposiderule | Hoffmann-La Roche | phase 3 | 284 running | TOP2B | ChEMBL |
| Daunorubicinrule | Kura Oncology | phase 3 | 72 running | – | ChEMBL |
| amrubicinrule | Bristol-Myers Squibb | phase 3 | 91 running | – | ChEMBL |
Also acted on by the same programs
Conditions their studies are in
- Breast Neoplasms, 2 programs
- Lung Neoplasms, 2 programs
- Lymphoma, Large B-Cell, Diffuse, 2 programs
- Small Cell Lung Carcinoma, 2 programs
- Carcinoma, Hepatocellular, 1 program
- Carcinoma, Non-Small-Cell Lung, 1 program
- Hematologic Neoplasms, 1 program
- Leukemia, Myeloid, Acute, 1 program
- Ovarian Neoplasms, 1 program
- Sarcoma, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026Etoposide · Hoffmann-La Roche · phase 3 · NCT07136285
- Dec 31, 2026Doxorubicin · Hoffmann-La Roche · phase 4 · NCT06526923
- Dec 2027Daunorubicin · Kura Oncology · phase 3 · NCT07255872
- Oct 2029amrubicin · Bristol-Myers Squibb · phase 3 · NCT06801834
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.